Insmed - Stock Price History | INSM

Historical daily share price chart and data for Insmed since 2021 adjusted for splits. The latest closing stock price for Insmed as of September 27, 2021 is 27.93.
  • The all-time high Insmed stock closing price was 195.00 on August 30, 2000.
  • The Insmed 52-week high stock price is 45.44, which is 62.7% above the current share price.
  • The Insmed 52-week low stock price is 22.00, which is 21.2% below the current share price.
  • The average Insmed stock price for the last 52 weeks is 32.68.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Insmed Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 28.2231 23.6600 40.5400 13.6300 33.2900 39.41%
2019 23.3077 13.9700 32.1900 13.9100 23.8800 82.01%
2018 22.6387 32.4600 32.9900 11.6000 13.1200 -57.92%
2017 20.2914 13.0800 31.7800 11.6100 31.1800 135.68%
2016 12.7351 17.2400 17.2400 9.0500 13.2300 -27.11%
2015 20.7534 15.9600 27.5400 14.1600 18.1500 17.32%
2014 15.7364 17.1400 21.5400 11.6500 15.4700 -9.00%
2013 11.2478 6.9600 17.3300 5.7200 17.0000 154.11%
2012 4.3827 3.1500 8.0000 2.7000 6.6900 119.34%
2011 6.4065 6.4000 13.1500 2.6400 3.0500 -51.65%
2010 8.1390 7.7000 12.5000 5.7000 6.3080 -18.08%
2009 9.7689 4.9000 24.7000 4.1500 7.7000 64.71%
2008 6.0865 8.3000 9.1000 3.4990 4.6750 -43.33%
2007 8.8034 9.0000 15.6000 5.7700 8.2500 -6.25%
2006 16.1210 21.3000 31.2000 8.5000 8.8000 -55.33%
2005 12.6992 23.0000 23.0000 8.2000 19.7000 -10.41%
2004 23.1546 30.3000 40.9000 10.1000 21.9900 -25.96%
2003 20.0198 4.8000 34.2000 4.1000 29.7000 561.47%
2002 17.7447 39.4000 39.4000 3.5000 4.4900 -88.25%
2001 45.0069 37.5000 89.9000 24.7000 38.2000 10.12%
2000 120.0576 164.8000 195.0000 26.8800 34.6900 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.219B $0.164B
Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29